Related references
Note: Only part of the references are listed.214: Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination with Rosuvastatin in Patients with Mixed Dyslipidemia: A Phase 3 Study
Peter H. Jones et al.
Journal of Clinical Lipidology (2008)
The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin
A. S. Windass et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
Pertti J. Neuvonen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Role of BCRP 421C>A polymorphism on rosuvastatin pharynacokinetics in healthy Chinese males
Wei Zhang et al.
CLINICA CHIMICA ACTA (2006)
ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein
LY Huang et al.
DRUG METABOLISM AND DISPOSITION (2006)
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
E Lee et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites
JT Backman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3α-hydroxy isomeric metabolite
LE Gustavson et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Taking aim at HDL-C - Raising levels to reduce cardiovascular risk
ME McGovern
POSTGRADUATE MEDICINE (2005)
Population pharmacokinetics of rosuvastatin in normal subjects and subjects with dyslipidemia.
T Tzeng et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans
AJ Bergman et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Effectiveness of statin therapy in adults with coronary heart disease
TJ Wilt et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
DW Schneck et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study
N Sattar et al.
CIRCULATION (2003)
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance
C Kyrklund et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers
PD Martin et al.
CLINICAL THERAPEUTICS (2003)
Gemfibrozil greatly increases plasma concentrations of cerivastatin
JT Backman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Effects of fibrates on metabolism of statins in human hepatocytes
T Prueksaritanont et al.
DRUG METABOLISM AND DISPOSITION (2002)
Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers
PD Martin et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Mechanistic studies on metabolic interactions between gemfibrozil and statins
T Prueksaritanont et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Prevalence of the metabolic syndrome among US adults - Findings from the Third National Health and Nutrition Examination Survey
ES Ford et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate
C Kyrklund et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Plasma concentrations of active simvastatin acid are increased by gemfibrozil
JT Backman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers
WJ Pan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Share Paper
